Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept

American Journal of Transplantation, Journal Year: 2021, Volume and Issue: 21(12), P. 4043 - 4051

Published: Aug. 25, 2021

Poor responses to mRNA COVID-19 vaccine have been reported after 2 injections in kidney transplant recipients (KTRs) treated with belatacept. We analyzed the humoral response belatacept-treated KTRs without a history of SARS-CoV-2 infection who received three BNT162b2-mRNA vaccine. also investigated immunogenicity prior and characterized symptomatic infections KTRs. Among 62 (36 [58%] males), median age (63.5 years IQR [51–72]), history, only four patients (6.4%) developed anti-SARS-CoV-2 IgG low antibody titers (median 209, [20–409] AU/ml). 71% were mycophenolic acid 100% steroids association In contrast, all 5 induced strong high 10 769 AU/ml, [6410–20 069]) two injections. Seroprevalence three-vaccine doses 35 non-belatacept-treated was 37.1%. Twelve vaccination, including severe forms (50% mortality). Breakthrough occurred 5% fully vaccinated patients. Administration third dose BNT162b2 did not improve belatacept COVID-19. Other strategies aiming patient protection are needed.

Language: Английский

---

Natural products and phytochemicals as potential anti‐SARS‐CoV‐2 drugs

Phytotherapy Research, Journal Year: 2021, Volume and Issue: 35(10), P. 5384 - 5396

Published: June 16, 2021

The current pandemic responsible for the crippling of health care system is caused by novel SARS-CoV-2 in 2019 and leading to coronavirus disease (COVID-19). virus enters into humans attachment its Spike protein (S) ACE receptor present on lung epithelial cell surface followed cleavage S cellular transmembrane serine protease (TMPRSS2). After entry, RNA genome released cytosol, where it highjacks host replication machinery viral replication, assemblage, as well release new particles. major drug targets that have been identified through host-virus interaction studies include 3CLpro, PLpro, RNA-dependent polymerase, proteins. Several reports natural compounds along with synthetic products displayed promising results some them are Tripterygium wilfordii, Pudilan Xiaoyan Oral Liquid, Saponin derivates, Artemisia annua, Glycyrrhiza glabra L., Jinhua Qinggan granules, Xuebijing, Propolis. This review attempts disclose anti-SARS-CoV-2 based silico prediction effect a variety phytochemicals either alone and/or combination conventional treatments their possible molecular mechanisms involved both prevention treatment disease.

Language: Английский

---

SARS-CoV-2 Infection Is Associated with an Accelerated eGFR Decline in Kidney Transplant Recipients up to Four Years Post Infection

Diagnostics, Journal Year: 2025, Volume and Issue: 15(9), P. 1091 - 1091

Published: April 25, 2025

Background/Objectives: Although kidney transplant recipients (KTRs) who are immune-compromised have been shown to be at high risk of adverse acute COVID-19 outcomes (i.e., mortality and critical illness), the long-term KTRs with a history SARS-CoV-2 infection unknown. We aimed compare without exposure SARS-CoV-2. Methods: This study retrospectively evaluated 1815 in Montefiore Health System from 4 January 2001 31 2024. The final cohorts consisted survived (n = 510) matched 510, controls). Outcomes were defined as all-cause changes estimated glomerular filtration rate (eGFR) urine protein creatinine ratio (UPCR) 30 days up four years post index date. Kaplan–Meier survival analysis Cox proportional modeling performed for mortality. Generalized estimating equations used analyze eGFR UPCR across time. Results: There was no significant group difference (adjusted hazard 0.66, [0.43, 1.01] p 0.057). controls patients before similarly decreased −0.98 units/year [−1.50, −0.46]. By contrast, declined significantly greater (−1.80 [−2.45, −1.15]) after compared COVID-19. association only seen among male not female KTRs. status associated change or rejection rate. Conclusions: an accelerated decline infection, suggesting potential implications graft health. These findings underscore importance vigilant monitoring management function this vulnerable population.

Language: Английский

---

Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: July 22, 2022

Vaccination against COVID-19 in patients with end-stage renal disease (ESRD) on replacement therapy and kidney transplant recipients (KTRs) is particularly important due to the high mortality rate. Here, we tested local systemic immunity novel Pfizer BioNTech (BNT162b2) messenger RNA (mRNA) ESRD, KTR patients, healthy individuals (150 subjects). The ESRD group was divided into: hemodialysis (HD) peritoneal dialysis (PD). We investigated based anti-N (nucleoprotein) anti-S (spike1/2) Immunoglobulin A (IgA) G (IgG) antibodies, respectively. Additionally, performed an Interferon gamma (IFN-γ) release test Interferon-gamma assay (IGRA) monitor cellular component of vaccine response. control had highest level IgG antibodies (153/2,080 binding antibody units (BAU)/ml) among all analyzed after 1st 2nd dose, HD (48/926 BAU/ml) a diminished compared PD (93/1,607 BAU/ml). Moreover, seroconversion rate dose lower than (56% vs. 86%). KTRs extremely low (33%). IgA-mediated most effective group, while other IgA production. observed percentage responders IFN-γ research participants (100% 85% control, 100% 80% PD, 97% 64% HD). 63% seropositive positive IGRA, 28% seronegative produced IFN-γ. Collectively, strongest response patients. Two doses are ineffective, especially KTRs. closer investigation required set clinical guidance. Clinical Trial Registration Number www.ClinicalTrials.gov , identifier: NCT04 905 862

Language: Английский

---

Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis

PLoS neglected tropical diseases, Journal Year: 2021, Volume and Issue: 15(6), P. e0009156 - e0009156

Published: June 15, 2021

Background The novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) replacement therapy (RRT) might have a higher CFR due to reduced immune function from uremia kidney tropism of but there was lack systematic study on the infection mortality SARS-CoV-2 in ESRD RRT. Methodology/Principal findings We searched five electronic databases performed review meta-analysis up June 30, 2020, evaluate case fatality rate COVID-19 global data were retrieved international database for estimating general population as referencing points. Of 3,272 potential studies, 34 eligible studies consisted 1,944 confirmed cases 21,873 RRT 12 countries four WHO regions. overall pooled 3.10% [95% confidence interval (CI) 1.25–5.72] which than 0.14% average prevalence. estimated 18.06% (95% CI 14.09–22.32) at 4.98%. Conclusions This suggested high should their specific protocol prevention treatment mitigate excess deaths.

Language: Английский

---

Booster effect of the fourth dose of the SARS-CoV-2 mRNA vaccine in kidney transplant recipients

Clinical and Experimental Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Language: Английский

---

Renal involvement in COVID-19: focus on kidney transplant sector

Infection, Journal Year: 2021, Volume and Issue: 49(6), P. 1265 - 1275

Published: Oct. 5, 2021

Language: Английский

---

Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience

Critical Care Research and Practice, Journal Year: 2024, Volume and Issue: 2024, P. 1 - 9

Published: May 2, 2024

Background. Kidney transplant recipients (KTRs) are a vulnerable immunocompromised population at risk of severe COVID-19 disease and mortality after SARS-CoV-2 infection. We sought to characterize the post-infection sequelae in KTRs our center. Methods. studied all adult (with functioning allograft) who had their first episode infection between 04/2020 04/2022. Outcomes interest included factors for hospitalization, all-cause mortality, COVID-19-related allograft failure. Results. Of 979 with infection, 381 (39%) were hospitalized. In multivariate analysis, hospitalization advanced age/year (HR: 1.03, 95% CI: 1.02–1.04), male sex 1.29, 1.04–1.60), non-white race 1.48, 1.17–1.88), diabetes as cause ESKD 1.77, 1.41–2.21). Vaccination was associated decreased 0.73, 0.59–0.90), 0.52, 0.37–0.74), 0.47, 0.31–0.71) univariate analyses. Risk both analyses age, respiratory symptoms hospital admission. Furthermore, additional analysis being recipient ESKD, living donor protective. Conclusions. Hospitalization due COVID-19-associated is increased mortality. protective factor against

Language: Английский

---

Comparative evaluation of Luminex based assays for detection of SARS-CoV-2 antibodies in a transplantation laboratory

Journal of Immunological Methods, Journal Year: 2023, Volume and Issue: 517, P. 113472 - 113472

Published: April 12, 2023

Language: Английский

---

Risk factors for mortality in kidney transplant recipients with COVID‐19: a single centre experience and case–control study

BMC Nephrology, Journal Year: 2022, Volume and Issue: 23(1)

Published: July 7, 2022

Abstract Background COVID-19 infection is considered to cause high mortality in kidney transplant recipients (KTR). Old age, comorbidities and acute injury are known risk factors for increased KTR. Nevertheless, rates have varied across different regions. Differences varying standards of care geographies may explain some variations. However, it still unclear whether post-transplant duration, induction therapy, antirejection therapy co-infections contribute KTR with COVID-19. The present study assessed a large cohort from India. Methods A matched case–control was performed analyze death ( N = 218) diagnosed between April 2020 July 2021 at the centre. Cases were who died (non-survivors, 30), whereas those survived taken as controls (survivors, 188). Results death-to-case ratio 13.8% observed amongst group infected There incidence (12.4%) co-infections, cytomegalovirus being most common co-infection among non-survivors. Diarrhea, co-infection, oxygen requirement, need mechanical ventilation significantly associated on regression analyses. Antirejection lymphopenia requirement renal replacement worse outcomes. Conclusions much higher required had co-infections. Mortality did not vary type transplant, duration usage depletion therapy. An aggressive approach has be an early diagnosis therapeutic intervention infections.

Language: Английский

---